Compare Emerson Electric Co. (EMR) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Emerson Electric Co. vs Neurocrine Biosciences Inc — how do they compare? Emerson Electric Co. trades at $159.06 (market cap $88.72B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B). The key difference: Emerson Electric Co. is far larger — about 6.2× Neurocrine Biosciences Inc's market cap, and Emerson Electric Co. pays a 1.4% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Emerson Electric Co. for 81 Days and Neurocrine Biosciences Inc for 23 Days on average.
| EMR | NBIX | |
|---|---|---|
Market Cap | $88.72B | $14.36B |
Volume | 2,355,255 | 1,237,180 |
Sector | Industrials | Health |
52-Week High | $164.38 | $185.50 |
52-Week Low | $123.30 | $123.10 |
Typical Hold Time | 81 Days | 23 Days |
Enterprise Value | $99.80B | $14.37B |
Dividend Yield | 1.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Emerson Electric (EMR) trades at $159.22, down 1.34% on the day, near its pivot point of $159. The stock shows a bullish technical trend with moving averages supporting upside momentum. Fundamentally, EMR delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $1.71 exceeding the $1.68 estimate. Revenue growth is steady, projected to reach $18.6B in 2026, while profitability remains solid with a net income margin of 13.83% in 2025.
The outlook for EMR is positive, supported by analyst consensus favoring a Buy rating (53.49%) and a $165.90 price target implying ~4% upside. Key risks include volatile cash flows, with net cash flow negative in 2025, and elevated debt levels. Investor sentiment is bolstered by strong institutional coverage and recent dividend declarations, though macroeconomic pressures on industrials warrant caution.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
